{"title":"An interview with Giuseppe Argenziano: an insight into the field of dermoscopy.","authors":"Giuseppe Argenziano","doi":"10.2217/mmt-2016-0025","DOIUrl":null,"url":null,"abstract":"<p><p><b>Giuseppe Argenziano speaks to Sebastian Dennis-Beron, Commissioning Editor:</b> Giuseppe Argenziano is Full Professor and Head of the Dermatology Unit at the University of Campania, Naples, Italy. His main research field is dermato-oncology. He is an author of numerous scientific articles and books concerning dermoscopy, a new technique improving the clinicians detection of benign and malignant skin tumors. As a coordinator of a Skin Cancer Unit, he has established a successful tertiary, multidisciplinary, referral center particularly devoted to the diagnosis and management of patients with skin tumors. Over the past 20 years he has supervised over 100 foreign students and 40 residents in dermatology, established scientific collaborations with more than 200 colleagues from more than 30 nations, and organized more than 50 national and international scientific activities, courses and conferences (such as the Consensus Net Meeting on Dermoscopy and the First Congress of the International Dermoscopy Society). He is co-founder and past president of the International Dermoscopy Society; project leader for the development of a high diagnostic technology oncologic center at the Arcispedale Santa Maria Nuova IRCCS in Reggio Emilia; faculty member of the Master of Science in Dermoscopy and Preventive Dermato-oncology and has undertaken a short course in dermoscopy, two e-learning courses by the Medical University of Graz and by Cardiff University, respectively; and member of the Editorial Board of the Journal of the American Academy of Dermatology. Professor Argenziano has authored more than 400 full scientific articles and produced landmark primary publications and books in the field of dermoscopy. Over the past 20 years, he has been invited as speaker and/or chairman in more than 500 national and international conferences in the field of dermatology. His combined publications have received a sum total of more than 8000 citations with an h-index value of 46.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2016-0025","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Melanoma Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/mmt-2016-0025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/3/3 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Giuseppe Argenziano speaks to Sebastian Dennis-Beron, Commissioning Editor: Giuseppe Argenziano is Full Professor and Head of the Dermatology Unit at the University of Campania, Naples, Italy. His main research field is dermato-oncology. He is an author of numerous scientific articles and books concerning dermoscopy, a new technique improving the clinicians detection of benign and malignant skin tumors. As a coordinator of a Skin Cancer Unit, he has established a successful tertiary, multidisciplinary, referral center particularly devoted to the diagnosis and management of patients with skin tumors. Over the past 20 years he has supervised over 100 foreign students and 40 residents in dermatology, established scientific collaborations with more than 200 colleagues from more than 30 nations, and organized more than 50 national and international scientific activities, courses and conferences (such as the Consensus Net Meeting on Dermoscopy and the First Congress of the International Dermoscopy Society). He is co-founder and past president of the International Dermoscopy Society; project leader for the development of a high diagnostic technology oncologic center at the Arcispedale Santa Maria Nuova IRCCS in Reggio Emilia; faculty member of the Master of Science in Dermoscopy and Preventive Dermato-oncology and has undertaken a short course in dermoscopy, two e-learning courses by the Medical University of Graz and by Cardiff University, respectively; and member of the Editorial Board of the Journal of the American Academy of Dermatology. Professor Argenziano has authored more than 400 full scientific articles and produced landmark primary publications and books in the field of dermoscopy. Over the past 20 years, he has been invited as speaker and/or chairman in more than 500 national and international conferences in the field of dermatology. His combined publications have received a sum total of more than 8000 citations with an h-index value of 46.
Giuseppe Argenziano是意大利那不勒斯坎帕尼亚大学皮肤科的全职教授和主任。主要研究领域为皮肤肿瘤学。他是许多关于皮肤镜的科学文章和书籍的作者,这是一项改善临床医生对良性和恶性皮肤肿瘤检测的新技术。作为皮肤癌部门的协调员,他建立了一个成功的三级,多学科,转诊中心,特别致力于皮肤肿瘤患者的诊断和管理。在过去的20年里,他指导了100多名外国学生和40多名皮肤科住院医师,与来自30多个国家的200多名同事建立了科学合作关系,组织了50多场国内和国际科学活动、课程和会议(如皮肤镜共识网会议和国际皮肤镜学会第一届大会)。他是国际皮肤镜学会(International Dermoscopy Society)的联合创始人和前任主席;在雷焦艾米利亚的Arcispedale Santa Maria Nuova IRCCS开发高诊断技术肿瘤学中心的项目负责人;皮肤镜检查和预防性皮肤肿瘤学理学硕士的教员,并分别参加了格拉茨医科大学和卡迪夫大学的皮肤镜检查短期课程和两个电子学习课程;也是《美国皮肤病学会杂志》的编辑委员会成员。Argenziano教授在皮肤镜领域撰写了400多篇完整的科学文章,并出版了具有里程碑意义的主要出版物和书籍。在过去的20年里,他受邀在500多个国家和国际皮肤病学会议上演讲和/或担任主席。论文总引用8000余次,h指数为46。
期刊介绍:
Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.